OS and disease-specific survival. Kaplan-Meier estimates of (A) OS and (B) disease-specific survival among 101 patients with LBCL treated with axi-cel in cohorts 1 and 2 of phase 2. One patient’s event time for OS was updated from month 42 to month 39 after data cutoff and is not reflected in this figure. DSS, disease specific survival.